Endurance Bio Overview
- Year Founded
-
2025
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Endurance Bio General Information
Description
Developer of small molecule therapeutics designed to improve cellular function and treat metabolic and neurodegenerative diseases. The company offers orally bioavailable compounds, mitochondrial and lysosomal pathway activation, and regulation of cellular metabolism, enabling biopharmaceutical organizations to target disease mechanisms and support therapeutic development.
Contact Information
Website
endurance-bio.comCorporate Office
- 10080 North Wolfe Road South West 3
- Suite 300
- Cupertino, CA 95014
- United States
Corporate Office
- 10080 North Wolfe Road South West 3
- Suite 300
- Cupertino, CA 95014
- United States
Endurance Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 31-Dec-2025 | Completed | Clinical Trials - Phase 2 |
Endurance Bio Patents
Endurance Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260199293-A1 | 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies | Pending | 02-Dec-2022 | ||
| US-20250009714-A1 | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype | Pending | 02-Nov-2021 | ||
| EP-4355326-A1 | Therapeutically effective oral administration of a 2 arylbenzimidazole | Pending | 17-Jun-2021 | ||
| EP-4355326-A4 | Therapeutically effective oral administration of a 2 arylbenzimidazole | Pending | 17-Jun-2021 | ||
| US-20240307356-A1 | Therapeutically effective oral administration of a 2 arylbenzimidazole | Inactive | 17-Jun-2021 | A61K31/4184 |
Endurance Bio Signals
Endurance Bio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Remiges Ventures | Venture Capital | Minority |
Endurance Bio FAQs
-
When was Endurance Bio founded?
Endurance Bio was founded in 2025.
-
Where is Endurance Bio headquartered?
Endurance Bio is headquartered in Cupertino, CA.
-
What is the size of Endurance Bio?
Endurance Bio has 5 total employees.
-
What industry is Endurance Bio in?
Endurance Bio’s primary industry is Drug Discovery.
-
Is Endurance Bio a private or public company?
Endurance Bio is a Private company.
-
What is Endurance Bio’s current revenue?
The current revenue for Endurance Bio is .
-
Who are Endurance Bio’s investors?
Remiges Ventures has invested in Endurance Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process